Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Phase 2 Unknown 10 enrolled Hematology and Oncology Specialists

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Timeline

Start: 2001-09
Primary completion: —
Completion: 2005-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	20 mg/m2	Intravenous

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Summary

Timeline

Drugs

Indications